ARS Pharmaceuticals, Inc.SPRYEarnings & Financial Report
Nasdaq
SPRY Q3 2025 Key Financial Metrics
Revenue
$32.5M
Gross Profit
N/A
Operating Profit
$-53.2M
Net Profit
$-51.2M
Gross Margin
N/A
Operating Margin
-163.7%
Net Margin
-157.4%
YoY Growth
1471.6%
EPS
$-0.52
Financial Flow
ARS Pharmaceuticals, Inc. Q3 2025 Financial Summary
ARS Pharmaceuticals, Inc. reported revenue of $32.5M for Q3 2025, with a net profit of $-51.2M (-157.4% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $32.5M |
|---|---|
| Net Profit | $-51.2M |
| Gross Margin | N/A |
| Operating Margin | -163.7% |
| Report Period | Q3 2025 |
ARS Pharmaceuticals, Inc. Annual Revenue by Year
ARS Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $89.1M).
| Year | Annual Revenue |
|---|---|
| 2024 | $89.1M |
| 2023 | $30.0K |
| 2022 | $1.3M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $500000 | $2.1M | $86.6M | $8.0M | $15.7M | $32.5M |
| YoY Growth | N/A | N/A | 4900.0% | N/A | N/A | N/A | 3043.4% | 1471.6% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $233.2M | $227.6M | $222.0M | $217.6M | $351.2M | $327.3M | $313.5M | $372.8M |
| Liabilities | $2.4M | $3.7M | $6.7M | $16.6M | $94.4M | $98.3M | $121.2M | $225.1M |
| Equity | $230.8M | $223.9M | $215.2M | $201.0M | $256.8M | $229.0M | $192.3M | $147.7M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-17.4M | $-6.7M | $-7.3M | $-14.5M | $42.0M | $-40.7M | $-39.6M | $-47.0M |